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Abstract
Background: An elevated blood level of homocysteine is a risk factor for cognitive impairment
and dementia. Homocysteine can be lowered by folate and/or vitamin B12 supplementation;
antioxidants might also be required for optimal reduction in neurovascular tissue. This report
presents clinical and radiological findings from administering the antioxidant N-acetylcysteine
together with B vitamins to cognitively impaired patients with hyperhomocysteinaemia.
Methods: A case series (n = 7) performed in a semi-rural General Practice setting. Formal
cognitive assessments were performed in five patients, and radiological assessments in one patient,
before and after supplementation.
Results and discussion: The addition of N-acetylcysteine resulted in subjective clinical
improvement in all patients, and an objective improvement in cognitive scores in five patients. One
patient had radiological evidence of halted disease progression over a twelve month period.
Conclusion: N-acetylcysteine, together with B vitamin supplements, improves cognitive status in
hyperhomocysteinaemic patients. Randomized controlled clinical trials are required to formally
evaluate this treatment approach.
Background
Vitamin B12 is essential for two mammalian metabolic
reactions – the conversion of methylmalonyl-CoA to suc-
cinyl-CoA, and of homocysteine to methionine; the latter
reaction is also folate dependent [1]. Serum levels of
methylmalonic acid rise in B12 deficiency, whereas homo-
cysteine levels rise in both folate and B12 deficiency. The
advent of assays for these metabolites has facilitated the
detection of early and 'subtle' deficiencies of these vita-
mins [2].
Of these two metabolites, homocysteine has recently
attracted interest with regard to cognitive function and
aging. Elevated plasma homocysteine is associated with
an increased risk of vascular disease and vascular demen-
tia [3,4]. There are also widely confirmed reports of ele-
vated blood levels in patients with Alzheimer's disease
(AD) and mild cognitive impairment (MCI) [5-8]. Homo-
cysteine levels predict cognitive decline in healthy elderly
[9-11], and hyperhomocysteinaemia is an independent
risk factor for the development of dementia, including AD
[12,13]. However, not all studies confirm a relationship
between homocysteine and cognition [14-17].
Potential mechanisms by which homocysteine might
influence cognition include a direct toxicity on glutamate
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neurotransmission and cerebrovascular endothelium, an
indirect inhibition of transmethylation reactions in brain,
potentiation of amyloid neurotoxicity and promotion of
tau phosphorylation [18-20].
Such mechanisms suggest causality, but confirmation
requires evidence from randomized controlled interven-
tion trials. Three such trials are now underway. The VITAL
trial (VITamins to slow ALzheimer's disease) is a large (n
= 400) double-blind placebo-controlled trial to determine
whether high-dose B vitamin supplements slow cognitive
decline in subjects with established AD [21]. The VITAT-
OPS (VITAmins TO Prevent Stroke) study is a large (n =
8,000) multi-center, randomized, double blind, placebo-
controlled secondary stroke prevention trial to determine
whether the addition of B-supplements to current best
management reduces the incidence of recurrent vascular
events in patients with stroke or transient ischaemic
attacks; dementia is a secondary outcome measure [22].
VITACOG is a UK-based randomized placebo-controlled
trial of B-supplements in 300 elderly participants with
MCI to determine effects on brain atrophy and cognitive
function (AD Smith – personal communication).
Although plasma levels of homocysteine are largely deter-
mined by vitamin B12 and folate status, antioxidant ther-
apy might also be required for optimal reduction in
neurovascular tissue [23]. This report presents the effects
of administering the antioxidant N-acetylcysteine (NAC)
together with B vitamins in seven cognitively impaired
patients presenting to their General Practitioner (AMc)
with hyperhomocysteinaemia and/or B vitamin defi-
ciency. Patients and carers were informed of the rationale
for prescribing NAC, and of its use outside the scope of its
current product licence, in accordance with United King-
dom General Medical Council Guidelines [24].
Case presentations
Case 1
A 78 year old lady presented with fatigue, anxiety and
depression. She had angular cheilosis but was not anae-
mic (Hb 11.9, MCV 90), despite a profound vitamin B12
deficiency (11 ng/l) with normal serum and red cell folate
(12 µg/l and 299 µg/L). She had parietal cell antibodies
but a normal Schilling test. She '...felt better' after monthly
injections of hydroxo-B12 (1,000 µg) were commenced,
but nevertheless remained anxious.
A year later she developed memory impairment, with dif-
ficulty remembering names. She scored 21/30 on Mini-
mental state examination (MMSE) [25]. It was felt that she
had a dementia, perhaps with associated depression, and
she was commenced on an antidepressant (a selective
serotonin reuptake inhibitor). Her depression slowly
resolved but her cognitive decline continued.
A year later she scored 18/30 on MMSE and 28/70 on the
Alzheimer's disease assessment scale (ADAS-Cog) [26]. In
view of her persistent dementia despite regular hydroxo-
B12 injections, she was commenced on oral NAC (600 mg)
daily (Zambon Italia – Vicenza). Two weeks later her hus-
band reported a noticeable improvement in her memory.
She now remembered names and faces she previously
would have struggled to recall. Her MMSE improved to
21/30 and ADAS-Cog to 20/70. The areas of improvement
were in scores of orientation, copying skills, word-recall,
naming and commands.
Case 2
An 84 year old lady presented with a three year history of
short-term memory impairment and early Parkinsonism
for which she took L-dopa. She was otherwise well. She
scored 12/28 on the 6 Item Cognitive Impairment Test
(6CIT) [27]. Investigations revealed a total serum homo-
cysteine (tHcy) of 20.1 µmol/L (normal range <13µmol/
L), but normal serum vitamin B12 (309 ng/L), folate (9.2
µg/L) and red cell folate (464 µg/L). She was not anaemic,
but had borderline hypothyroidism (TSH 9.1 µmol/L).
In view of her elevated tHcy, and despite 'normal' serum
B vitamin levels, she was commenced on daily oral cyano-
B12 (1000 µcg), folic acid (5 mg) and NAC (600 mg).
Within one month her tHcy fell to 7.5 µmol/L. She was
assessed by a Psychogeriatrician three months after her
initial presentation. She now showed no significant cogni-
tive deficits; she scored 28/30 on MMSE.
The psychogeriatrician was '...particularly impressed that
she could provide the Christian names of all her five chil-
dren and twelve grandchildren without any problems'
and it was felt that she now had no obvious diagnosis of
a dementing illness.
Case 3
A 77 year old lady presented with a six month history of
confusion and memory loss. An aunt had early-onset AD.
On examination she was disorientated to time and had
demonstrable memory impairment. She was vitamin B12
deficient (172 ng/L) but with normal serum and red cell
folate (10.1 µg/L and 321 µg/l, respectively).
She commenced monthly intramuscular hydroxo-B12
injections (1,000 µg) but continued to deteriorate. She
became fatigued and developed visual hallucinations and
persecutory ideas. She had naming difficulties, her repeti-
tion was poor, and she had constructional dyspraxia. It
was felt she had probable AD. She was admitted for care,
scoring only 13/30 on MMSE. She was commenced on an
acetylcholinesterase inhibitor with slight initial improve-
ment (15/30). Nevertheless her condition continued toNutrition Journal 2006, 5:6 http://www.nutritionj.com/content/5/1/6
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deteriorate. She developed dysphagia and weight loss due
to a grade III oesophagitis.
Oral NAC (600 mg daily) was added to her treatment and
her family and carers noticed a significant improvement.
She became more alert and recognised her close family; a
formal cognitive assessment was not performed in view of
the severity of her dementia and associated physical con-
dition. Sadly she died from a bronchopneumonia several
weeks later.
Case 4
An 87 year old retired school headmistress presented with
a three year history of gradually deteriorating short-term
memory and general 'confusion'; she frequently mislaid
things and often wandered, forgetting her way home. She
had a past medical history of diverticular disease and an
osteoarthritic hip, but was otherwise well.
On examination it was felt she was suffering from a senile
dementia of moderate severity although no formal cogni-
tive scores were recorded. Routine investigations were
normal other than a highly elevated tHcy of 27.5 µmol/L.
She was commenced on folic acid 5 mg daily and oral
hydroxo-B12 1,000 mcg daily, together with NAC 600 mg
daily. Her tHcy fell to 6.6 µmol/L six-months later, at
which time she felt generally well although she remained
mildly confused. Her daughter commented on a marked
improvement in her general behaviour, although she
remained forgetful at times. Three years later she remains
very well and continues to be cared for at home with no
major difficulties.
Case 5
An 84 year old lady presented with a two year history of
increasing forgetfulness and confusion and no significant
previous illnesses. She was cared for at home by her
daughter. On formal examination she was disorientated
in time and place with demonstrable short-term memory
impairment.
It was felt she had a moderate dementia; she scored 55 out
of 70 on an ADAS-Cog assessment. Blood investigations
were normal other than an elevated tHcy of 16.4 µmol/L
and low red cell folate (157µg/l) (serum vitamin B12 and
folate were 281 ng/L and 4.4 µg/l respectively.) She was
not anaemic (Hb 12.7).
She was commenced on daily oral cyano-B12 (150  µg
daily) folic acid (5 mg) and NAC (600 mg) daily. One
month later she had gained ten points on ADAS-Cog
score. Her daughter also reported that she was '...generally
more settled and content, and less likely to wander.'
Follow-up radiological findings in Case 7 Figure 2
Follow-up radiological findings in Case 7: T2 weighted MRI 
scans of Case 7 showing extent of white matter disease in 
January 2006
Initial radiological findings in Case 7 Figure 1
Initial radiological findings in Case 7: T2 weighted MRI scans 
of Case 7 showing extent of white matter disease in January 
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Case 6
A 71 year old retired engineer presented with a ten year
history of gradually progressive short-term memory
impairment. His wife had become concerned because he
had recently lost his way driving to a regular address. He
complained of losing objects and forgetting people's
names.
His father had died of senile dementia aged 74, with
symptoms developing at aged 60 years. The patient him-
self had a past medical history of hypertension controlled
by beta-blocker. On cognitive examination he scored
poorly on 6CIT (12/28). Routine blood investigations
revealed elevated tHcy (15.6 µmol/L) with normal serum
vitamin B12 (368 ng/L), folate (9.3µg/L) and red cell folate
(492 µg/L).
He was commenced on daily oral cyano-B12 (1,000 µg)
folate (5 mg) and NAC (600 mg). His wife reported a
"...definite and immediate improvement" within two
weeks of commencing treatment. His tHcy fell to 9.6
µmol/L. He was seen by a Psychogeriatrician one month
later. He now scored 28/30 on MMSE with a CAMCOG of
115/125, indicating only a mild cognitive deficit [28]. A
diagnosis of "age-related cognitive impairment" was
made. He has continued on this treatment for the last two
years and continues to score well on cognitive assess-
ments. He scored 27/30 on his most recent assessment
and has now commenced an acetylcholinesterase inhibi-
tor in addition to B vitamin and NAC supplementation.
Case 7
A 75 year old retired College Lecturer presented with a
four year history of increasing forgetfulness. In particular
he frequently mislaid things, and had occasional difficulty
remembering people's names. His wife had become con-
cerned about his ability to drive. He had a past medical
history of prostatic carcinoma treated with radiotherapy,
anxiety/depression, and gastro-oesophageal reflux, but
was generally well in himself.
On cognitive examination he was disorientated in time
and had demonstrable short term memory impairment.
He scored 8/28 on 6CIT and 16/39 on TICS-m [29]. An
MRI scan showed several foci consistent with small vessel
disease (Figure 1). Blood investigations revealed raised
tHcy of 14.6 µmol/L, borderline low serum B12 (191 ng/
L), but normal folate (11.7 µg/L) and red cell folate (692
µg/L).
He was commenced on daily oral cyano-B12 (1000 µg),
folic acid (5 mg) and NAC (600 mg). After one month he
had gained five points on TICS-m (21/39). His tHcy fell to
8.3 µmol/L. He was personally delighted with the treat-
ment. His wife commented that "...he was becoming very
forgetful, quite retiring, quiet, sleepy all the time, not
NAC and intracellular B12 processing Figure 4
NAC and intracellular B12 processing: Potential role of the 
glutathione precursor NAC in intracellular vitamin B12 
metabolism (GSH = reduced glutathione).
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Details of the methionine synthase reaction Figure 3
Details of the methionine synthase reaction: Homocysteine 
reacts with the methyl group of methionine synthase-bound 
methyl-B12 to produce methionine and an unstable interme-
diate form of B12, cob(I)alamin. Cob(I)alamin then reacts with 
methyl-folate (CH3-THF) to generate free folate (THF) and 
regenerate methyl-B12. The vitamin shuttles between methyl-
B12 and cob(I)alamin states. Cob(I)alamin is occasionally deac-
tivated by oxidation to cob(II)alamin. Reductive remethyla-
tion of Cob(II)alamin requires a methyl group donated by S-
adenosylmethionine. Deactivation usually occurs every few 
hundred cycles, but AD and age-related oxidative stress 
might augment this process [23].
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interested in his food or in life. Now, there's a marked
improvement. We can discuss the news without any prob-
lem. He's reading again. He's interested in life once more."
One year later, he remains well and has successfully
regained his driving license following a formal assess-
ment. A repeat MRI scan showed no significant progres-
sion in the extent or size of the focal areas of abnormality
in the deep white matter, and no change in ventricular
configuration (Figure 2).
Conclusion
These reports demonstrate the apparent clinical efficacy of
the addition of NAC to B vitamin regimes in hyperhomo-
cysteinaemic patients with cognitive impairment. NAC
was well-tolerated in all patients; there were no reported
side-effects. Three similar case reports were described ear-
lier [30]. There is one previous study of NAC treatment
alone in AD patients [31]. This found a favourable effect
of NAC on nearly every outcome measure, although sig-
nificant differences were obtained only for a subset of cog-
nitive tasks.
There is now strong evidence that elevated blood levels of
homocysteine are associated with dementia in general,
including both vascular dementia and AD [32]. However,
the mechanism underlying this association remains
unclear. It may be due to a combination of adverse affects
of homocysteine on neurovascular tissue, in addition to
impairment of neurotransmitter synthesis due to defects
in methyl group metabolism [19,20]. The clinical
responses to NAC in these cases suggest that homo-
cysteine might also be a surrogate marker for the effects of
oxidative stress in these tissues [23].
NAC might act as an antioxidant, reducing the effects of
oxidative stress on the methionine synthase reaction [33]
(Figure 3). Additionally, it might facilitate intracellular
vitamin B12 processing by increasing levels of reduced glu-
tathione (Figure 4). Reduced glutathione is required for
the conversion of cyano-B12 and hydroxo-B12 to glutathio-
nyl-B12, prior to reduction to the enzymatically active
forms of the vitamin by cobalamin reductase [34]. NAC
also increases urinary excretion of homocysteine, leading
Ventura et al to suggest that this approach may be an
important associative or alternative therapy for hyperho-
mocysteinaemia [35].
The radiological findings in Case 7 are notable. Elevated
homocysteine levels are associated with brain atrophy and
white matter lesions [6,36,37]. The annual estimate of
progression of white matter lesions in cognitively intact
elderly individuals is approximately 0.6 mL/year [38,39].
Though not formally quantified, the apparent halting of
disease progression in Case 7 is of significance. Follow-up
scans were not performed in the earlier cases.
A notable feature in all cases was the complete absence of
anaemia. Indeed, despite the clear association between
metabolic evidence of B12 and/or folate deficiency and
dementia, anaemia and macrocytosis are invariably
absent in these patients [40]. The dissociation between
the neuropsychiatric and haematological features of these
deficiencies suggests that they may not always share a
common pathogenesis. Hyperhomocysteinaemia in these
patients potentially arises from oxidative depletion of vita-
min B12 and folate [23,41]. Such depletion is, of course,
subtly different from our current concepts of classical defi-
ciency due to malnutrition or malabsorption.
The epidemiological evidence is now of sufficient strength
that elevated levels of homocysteine should be considered
a potential risk factor for dementia in elderly patients [42].
At the very least, clinicians should determine the folate
and vitamin B12 status of these patients, irrespective of
whether or not there is a macrocytic anaemia.
Randomized controlled clinical trials are required to for-
mally evaluate the apparent beneficial effects of this syn-
ergistic approach to cognitively impaired
hyperhomocysteinaemic patients. However, these initial
studies suggest that disturbances of vitamin B12 and folate
metabolism may indeed be an important remediable fac-
tor in the aetiology of these fascinating but devastating
diseases.
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